Shanghai MicroPort MedBot Group Co. Ltd. (MEDBOT-B) stock is soaring 5.04% in Friday's trading session, following the release of its impressive unaudited consolidated interim results for the first half of 2025. The medical robotics company reported a substantial 77% year-on-year increase in revenue, reaching RMB175.7 million, driven by strong sales of medical devices and accessories.

The standout performance came from the company's overseas markets, where sales revenue surged by an remarkable 189% year-on-year to RMB102.4 million. This breakthrough in international commercialization has significantly contributed to the company's overall growth. Additionally, MicroPort MedBot reported that the comprehensive order volume for its core products in laparoscopic, orthopedic, and vascular intervention accumulated nearly 150 units, with over 100 units installed globally.

Despite reporting a net loss of RMB114.9 million for the period, investors appear to be focusing on the company's robust revenue growth and successful expansion into overseas markets. The company's strategy of enhancing cost and cash flow control, optimizing production processes, and improving operational management seems to be paying off, reshaping the global surgical robot market landscape. As MicroPort MedBot continues to prioritize both domestic and overseas markets through its dual-track strategy, the market is responding positively to its growth prospects in the competitive medical robotics sector.